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 Abstract - In 2005, the discovery of Janus kinase 2 
(JAK2) V617F mutation in approximately half of patients 
with myelofibrosis (MF) marked an important milestone in 
our understanding of the pathophysiology of MF. This has 
broadened our understanding of the disease pathogenesis 
and became the foundation for the development and 
subsequent clinical use of JAK inhibitors for MF. However, 
it is clear that other pathogenetic modifiers contribute to the 
disease diversity and phenotypic variability of MF. Novel 
genome scanning technologies were useful in the 
identification of recurrent molecular mutations in other 
genes including MPL, TET2, IDH1/2, DNMT3A, SH3B2 
(LNK) and CBL in MF pointing out that other pathways 
might be important in addition to the JAK/STAT pathway. 
The biologic role and clinical implications of these molecular 
mutations in MF is currently under investigation. The main 
challenge is to understand the mechanisms whereby 
molecular mutations whether alone or in combination with 
other genetic and non-genetic events contribute to the 
pathogenesis of MF and eventually can explain the 
phenotypic variability among the MF patients. In the present 
review we will provide an overview of the molecular 
pathogenesis of MF describing past and recent discoveries in 
molecular markers and their possible relevance in disease 
phenotype. 
 




I. INTRODUCTION: OVERVIEW OF PRIMARY 
MYELOFIBROSIS 
 
 Myelofibrosis (MF) is a Philadelphia chromosome 
negative myeloproliferative neoplasm (MPN) clinically 
characterized by disease related constitutional symptoms, 
extramedullary hematopoiesis (EMH) especially 
splenomegaly, leukoerythroblastosis and variable degrees 
of cytopenia. Pathologically, the bone marrow (BM) of 
MF patients demonstrates atypical megakaryocytes, 
megakaryocytic hyperplasia, thickening and distortion of 
bony trabeculae and fibrosis [1]. Clonal markers 
exemplified by cytogenetics can be helpful in diagnosis, 
prognosis and therapeutic stratification in myeloid 
malignancies. Key examples include t(9;22)(q34;q11) in 
chronic myeloid leukemia, 5q- in MDS with del5q 
abnormalities and inv(16)(p13;q22), t(16;16)(p13;q22), 
t(15;17)(q24;q21) and t(8;21)(q22;q22) in de novo acute 
myeloid leukemia. In MPN, the JAK2 V617F mutation 
provided one of the most important genetic findings in the 
non-Philadelphia chromosome myeloid malignancies. 
Many non-JAK2 clonal markers have been recently 
identified in  MF, including genes like MPL (exon 10)[2], 
TET2 [3], ASXL1 [4], IDH1/2 [5], DNMT3A [6], EZH2 
[7], CBL [8] and SH2B3 (LNK). Their exact role in the 
development of disease specific phenotypic features and 
clinical manifestations in MF is currently the subject of 
investigation but will likely provide new insight into 
disease specific mechanisms. For example, the ring 
sideroblast phenotype of MDS and even MF, mastocytosis 
and pure red cell aplasia patients can be explained by 
mutations in the SF3B1 gene [9]. Identification of 
phenotype-genotype associations specific to individual 
genetic mutations will hopefully translate to new 
therapeutic options for patients with MF that can lead to 




II. MOLECULAR MUTATIONS  
IN THE PATHOPHYSIOLOGY  
OF MYELOFIBROSIS 
 
 JAK2 (exon 14): the discovery of mutations in the 
Janus kinase 2 (JAK2) signalling pathway opened a new 
perspective in the pathophysiology and treatment of MF 
[10]. The frequency of JAK2V617F mutation ranges 
between 43-59% in MF. The most commonly detected 
mutation results in a guanine to thymine change at 
nucleotide 1849 [11].  JAK2 is a member of JAK family 
(JAK1, JAK3 and TYK2) proteins which are cytoplasmic 
non-receptor tyrosine kinases with a significant function 
in cell proliferation and survival of hematopoietic stem 
cells (HSC). The JAK2V617F mutation is essential for 
self-reprogramming properties of HSC and it has been 
associated with some phenotypes of MF. Experiences in 
transgenic mice showed that, a low level of JAK2V617F 
load can induce essential thrombocytosis (ET)-type 
features, while the higher levels of mutant alleles can 
cause polycythemia vera (PV) and MF-like phenotypes 
[12]. However, the presence of this mutation cannot 
consolidate all other MF related findings including 
cytopenia and the tendency of MF to transform to acute 
myeloid leukemia (AML) which is observed in 5-10% of 
patients with MF [13]. Determination of the molecular 
basis for the constitutive activation of JAK2V617F is 
crucial for understanding its clinical implication. It has 
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been elucidated that the position at amino acid 617 it is 
important for protein-protein interaction. Mutations at 
position 617 induce autophosphorylation, gene 
transcription and in vitro kinase activity of JAK2 [14]. 
Recently, it was reported that activation of JAK2 can 
promoting the activation of three homodimeric myeloid 
receptors like EPO-receptor, MPL (TPO-receptor), and 
GM-CSF (Figure 1)[15].  
Beside its role in mediating the signalling pathways 
of EPO and MPL, JAK2 signal can induce the over-
expression of several oncogenes like LIM domain only 2 
(LMO2) by an epigenetic regulation. JAK2 signal can re-
model the chromatin structure by phosphorylating the 
histone H3Y41 and consequently blocking the recruitment 
of the repressor heterochromatin 1α leading to over-
expression of LMO2 [16].  
 
JAK2 (exon 12): a gain-of-function mutation in exon 
12 is detected in a small proportion (3-5%) of JAK2 wild 
type (WT) MF patients. Murine studies have shown that 
mutations in this exon impacts erythrocyte proliferation 
[17]. New alterations (deletions, insertions, substitutions) 
were found in positions 537 through 543. However, it is 
still unclear how these mutations can alter the function of 
JAK2 [17].  It has been elucidated that exon 12 links to 
SRC homology 2 (SH2) and JH2 domains of JAK2. 
Compared to V617F mutation, molecular alterations in 
exon 12 produce higher ligand-independent signaling and 
phosphorylation through JAK2 [17].  In humans, these 
mutations are associated with younger age, lower level of 
erythropoietin, and lower predominance of erythroid 
myeloproliferation [18]. Patients with polycythemia vera 
(PV) harboring mutations in exon 12 seem to be 




Figure 1. JAK2 receptor signaling and activation of STAT pathway. The binding of erythropoietin (EPO) to a receptor results in receptor 
dimerization of JAK2. This dimerization leads to phosphorylation of STAT3 and 5 and formation of stable homodimers and heterodimers which 
subsequently induce transcription of genes that regulate the cell proliferation and survival. The JAK2V617F mutation can cause the monotonous 
activation of STAT pathway in the absence of any other trigger.  Furthermore, activation of MPL can initiate the downstream signaling cascade of 
JAK2 via recruitment of Src homology 2 (SH2) which can stimulate RAS protein and phosphoinositide-3 kinase (PI3K) leading to transcriptional 
activity of certain genes. 
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MPL (Myeloproliferative Leukemia Virus): the 
absence of JAK2V617F in some MF patients suggests the 
presence of alternative mechanism(s) that can activate the 
JAK/STAT pathway (Figure 1)[19]. MPL W515L/K can 
be detected in 5-10% in MF patients and appears to be a 
gain-of-function mutation [20-21]. The MPL gene encodes 
a 635 amino acid protein called CD110.  CD110 has 4 
functional domains including a putative signal peptide, an 
extracellular domain, a transmembrane domain, and an 
intracellular domain [22]. The ligand, thrombopoietin 
(TPO) can lead to dimerization of CD110 and subsequent 
downstream activation of the JAK-STAT pathway.  The 
CD110-TPO is important in renewal of HSC and in the 
development and proliferation of megakaryocytes and 
platelets [23]. The relationship between MPL W515L/K 
and the pathogenesis of MF are based on several 
important disease observations: 1) MPL W515L/K are 
found in the amphipathic KWQFP motif of CD110 which 
is important in preventing spontaneous activation of 
CD110, 2) Nude mice injected with MPL-transduced 
Ba/F3 cells developed subcutaneous tumors and 
splenomegaly [24], and 3) BM transplantation assays 
conducted by injecting murine cells with W515L mutation 
led to features of ET and tendency of rapid evolution to 
MF [25].  
 
TET2 (Ten Eleven Translocation-2): TET2 is a 
tumor suppressor gene located in a small region (0.35 Mb) 
of chromosome 4 (4q24). Mutations of this gene are 
frequently detected in various myeloid malignancies. In 
MPN, TET2 has a frequency of 15-25% in PMF, 15-20% 
in post-PV MF, 10-15% in post-ET MF and 20-25% in 
MF that have progressed to AML [26]. This molecular 
mutation can occur in conjunction with JAK2V617F 
mutation leading to a bi-clonal model or can precede the 
JAK2 mutational event during disease formation [26-27]. 
TET2 mutations can lead to truncated proteins resulting in 
a total or partial loss-of-function.  It has been postulated 
that molecular alterations in this gene may have been one 
of the first events in early hematopoiesis [27]. In addition, 
the epigenetic role of TET2 has been studied [28]. TET2 
catalyzes the conversion of the 5-methylcytosine (5-MC) 
to 5-hydroxymethylcytosine (5-hMC) by oxidizing 5-MC. 
In patients carrying TET2 mutations, the level of 5-hMC is 
lower than WT with variability across diseases (lower in 
myelodysplastic syndromes (MDS) and higher in 
AML)[29]. In human hematopoiesis, knock-down of 
TET2 resulted in increased monocytes differentiation and 
decreased erythroid proliferation [16]. In a study 
conducted in our laboratory, TET2 mutations were not 
present in JAK2 WT MF patients in comparison to JAK2 
mutant counterpart [30]. This observation was also 
reported by other investigators (Figure 2)[31].  
 
ASXL1 (Additional Sex Combs-like 1): ASXL1 is a 
polycomb gene required for long-term repression of the 
HOX genes. Genetically, in Drosophila, Asx gene behaves 
like an inducer of the trithorax complex. In general, 
polycomb genes are important in the manifestation of the 
bidirectional homeotic phenotypes suggesting their roles 
in the activation and silencing of HOX genes [32]. ASXL1, 
is a potential epigenetic modifier, and mutations of this 
gene cam cause the loss of polycomb repressive complex 
2 (PRC2)-mediated histone H3 lysine 27 (H3K27) tri-
methylation which results in the transcriptional repression 
in hematopoietic cells [33].  
 Loss of ASXL1 can lead to the depletion of 
PRC2 and H3K27 involvement in myeloid leukemic cells 
which can cause the perturbation of polycomb-mediated 
gene silencing. It was elucidated that dysregulation of this 
interaction can make the cells prone to leukemia 
transformation [33]. In addition, it has been shown to 
down-regulate the retinoic acid receptor signaling which 
can alter the transcription of particular genes [34]. The 
frequency of ASXL1 mutations in MF is about 15-20% 
albeit, in overlap syndromes particularly in chronic 
myelomonocytic leukemia (CMML) half of the patients 
acquire those mutations [35-36]. It was reported that 
ASXL1 mutations are usually mutually exclusive with 
JAK2V617F even though in one study ASXL1 mutations 
were noted in conjunction with JAK2V617F or TET2 
mutations rather than IDH1 [35]. ASXL1 mutations are 
usually seen in exon 12 and are missense, frame-shifts, 
and duplications in the case of the controversial variant 
(p.Gly646TrpfsX12)[35].  
 
CBL (Casitas B-cell Lymphoma): CBL gene is 
located in the long arm of chromosome 11 (11q23.3) and 
encodes for a cytosolic protein with dual functionality; 1)  
down regulates tyrosine kinase signaling trigged by E3 
ubiquitin ligase which leads to internalization and 
lysosomal/ proteosomal degradation and 2) modulation of 
downstream signaling of JAK2 and MPL [37].  In cell 
culture studies, a CBL mutation induces oncogenic 
phenotype and proliferation with activating the RAS-
pathway in the absence of growth factor stimulation [37]. 
CBL knockout mice manifested splenomegaly, HSC 
proliferation, and sensitivity to growth factors [38]. The 
mutations of this gene were first described in AML as 
MLL-CBL fusion (MLL, exon 6 and CBL, exon 8) 
resulted in induction of the FLT3 signaling. (38) CBL has 
been considered a tumor suppressor gene. The frequency 
of mutant CBL is about 15-20% and 3-6% in CMML and 
PMF, respectively [39]. The mutations are mainly 
missense or in-frame deletions and usually coexist with 
JAK2, TP53, FLT3 and RUNX1 mutations [40]. However, 
some studies have shown that at the time of disease 
progression, CBL mutations can occur after JAK2V617F 
mutation suggesting that two different cell lineages harbor 
these mutations [37].  
 
IDH1/2 (Isocitrate Dehydrogenase 1/2): IDH1/2 
are homodimeric NADP
+
 dependent enzymes involved in 
the conversion of isocitrate to α-ketoglutarate by oxidative 
decarboxylation prior to NADPH synthesis [41]. 
Heterozygous mutations of these genes were first 
described in gliomas and secondary glioblastomas and 
then in AML [42-43]. Mutations in IDH1/2 can lead to an  
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Figure 2. Krebs cycle to DNA methylation. IDH1/2 wild-type enzymes convert isocitrate to α-ketoglutarate (αKG), a TET2 substrate. IDH1/2 
mutations result in neomorphic enzymes converting αKG to 2-hydroxyglutarate (2HG) which is an oncometabolite. 2HG can compromise the function 
of TET2. In addition, TET2 and DNMT3A genes are involved in epigenetic transcriptional regulation by maintaining the DNA methylation during DNA 
replication and cell division. 
increase in NADPH-dependent reaction of α-ketoglutarate 
resulting in over production of α-hydroxyglutarate which 
is a potential toxic substance and conversely have a 
negative effect on the function of the TET2 protein 
(Figure 2)[44]. IDH1/2 mutations usually involve the 
amino acid R132 and R172, respectively. The frequency 
of IDH1/2 mutation is about 3-5%, 1-2%, and 10-20% in 
PMF, post-PV/ET MF and in MF cases evolving to AML 
[45].  Furthermore, mutations in these genes are usually 
observed to be mutually exclusive from mutations of 
JAK2, TET2, and MPL [39]. In addition, in gliomas the  
presence of IDH1/2 mutations correlated to treatment 
response to chemotherapy. A study conducted in MPN has 
correlated the presence of a panel of molecular mutations 
including IDH1/2 with a failure to response to treatment 
with PEG-interferon-. Ultimately, IDH1/2 
mutations have been associated with transformation to 
AML even though it is not clear at this time where it falls 
in the hierarchy of mutational events in clonal evolution 
[46].  
DNMT3A (cytosine-5-methyltransferase 3-α): the 
DNMT3A heterozygous mutations were initially described 
in AML and MDS with a frequency of 5-22% [47]. 
However, in MF its frequency is lower (5 -12%)[48]. This 
gene encodes a DNA methyltransferase that is essential in 
de novo methylation. Acquisition of mutations can cause 
loss-of-function resulting in homo-dimerization and 
activation of the protein, reduction of the activity of 
methyltransferase, and consequent increased cell 
proliferation [48]. This gene can play a significant role in 
progression of MPN to AML in the presence of JAK2 and 
MPL mutations. It has been showed that the time of 
mutational event acquisition reflects the disease course 
[49]. In order to further dissect the role of this gene in 
MPN, a study described the isolation of different cellular 
lineages and the successive assessment of the cell type 
harboring high frequency of DNMT3A mutations. 
Mutations were identified with high frequency in CD14
+
 





 (T and B lymphocytes, respectively) 
suggesting that the aberrant clone does not occur in 
lymphoid lineages [49]. Indeed, DNMT3A mutations are 
associated with over expression of other relevant genes in 
advanced myeloid malignancies [48].  
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SH2B3 (LNK): the lymphocyte (LNK or SH2B3) 
adaptor protein is a member of the SH2B family and plays 
an important role in hematopoiesis and cytokine 
regulation. The protein encoded by this gene is a plasma 
adaptor component which binds to JAK2 and inhibits the 
JAK/STAT signal transduction pathway [50]. In addition, 
LNK negatively regulates the EPO receptor and MPL 
signaling resulting in the inhibition of the JAK-STAT 
pathway [51]. In JAK2V617F mutant patients, LNK 
expression may increase which contributes to the 
developing of myeloproliferative phenotype [14]. LNK-
deficient mice showed a phenotype similar to MPN 
patients like splenomegaly, thrombocytosis, leukocytosis, 
abnormal megakaryocytes, and BM fibrosis [52]. The 
prevalence of LNK mutations is low (<5%) in MPN; 
however it is slightly higher (10-13%) in leukemic 
transformation of MF patients [53]. Concomitant 
mutations in JAK2V617F and LNK were associated with 
disease evolution [54]. In another study, LNK deficiency 
in mice increased cytokine independent- JAK-STAT 
signaling and also cooperates with JAK2 activation in the 
development of a MPN like phenotype [55].  
EZH2 (enhancer of zeste homolog 2): this gene is 
located in chromosome 7 (7q36.1) and belongs to the 
complex 2 of Polycomb, a mediator of transcriptional 
silencing and a regulator of multiple cellular process like 
proliferation, maturation, aging and hematopoietic cell 
plasticity [56]. EZH2 over-expression is noted in a variety 
of solid tumors like prostate and breast cancer and it has 
been reported to contribute to tumor aggressiveness and 
poor cellular differentiation [57]. EZH2 mutations appear 
to be a gain-of-function genetic change acting as a 
repressor by methylating the histone H3 on lysine 27 
(H3K27) and consequently inactivating the chromatin 
[58]. The frequency of EZH2 mutations is approximately 
12% in MF; however, mutations are not exclusively found 
in MPN since they are more frequent in MDS (2-6%) and 
MDS/MPN (~15%). Clinically, EZH2 mutations have 
been associated with poor prognosis [7].  
 
RNA Splicing Machinery: the recurrent mutations 
in genes encoding for different members of the RNA 
spliceosome machinery (SF3B1, SRSF2, U2AF1 and 
ZRSR2) have been reported in myeloid malignancies in 
relatively high frequency (MDS with ring sideroblast 
 
Figure 3. RNA Splicing machinery. RNA splicing is a mechanism in which non-coding regions (introns) are removed and coding regions (exons) 
strip to form a mature RNA. The GU dinucleotide at the 3’ and terminal AG dinucleotide at the 5’ ends serve as specific recognition sites. Several 
proteins forming complexes called: spliceosomes (U1, U2, SF1, U2AF) are involved in the removal of an intron lariat and assist in further steps in the 
formation of a mature messenger RNA. 
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~86%, MDS without ring sideroblast ~44%, and in 
CMML ~55%)[59]. All of the previously identified 
spliceosome genes are involved in the 3΄-splice site 
recognition of a premature RNA. The U2 small nuclear 
RNA auxiliary factor 1 (U2AF1), establishes a substantial 
interaction with the serine/ argentine domain of another 
splicing factor called SRSF2 resulting in the exposure of 
the 3΄-splice site and adjacent polypyrimidine tract. This 
synergism provides the possibility of actively recruiting 
also SF3B1 in the formation of the splicing A complex 
and in the formation of a mature RNA (Figure 3). 
Molecular alterations in these genes can cause defect in 
splicing of downstream targets. U2AF1 and SRSF2 have 
been associated with leukemogenesis [60]. The role of 
SRSF2 in genomic stability has also been studied. Indeed, 
perturbation of the function of this gene resulted in 
double-strand DNA breaks [60]. SF3B1 mutations have 
been associated with good clinical outcomes and ring 
sideroblast formation in MDS [9,61]. We reported the 
presence of an SF3B1 mutation (K700E) in a patient with 
MF whose BM erythroid precursors also showed 
occasional ring sideroblast further supporting the role of 
SF3B1 mutation on the pathogenesis of ring sideroblast 
formation even in non-MDS myeloid neoplasms [62]. The 
clinical relevance of ZRSR2 remains unclear due to the 
low frequency (3.1%) of mutations in MDS [63]. In our 
laboratory we have been actively working in defining the 
frequency of the three most prevalent spliceosome genes  
in MDS (SF3B1, U2AF1, SRSF2) in a cohort of 130 
patients with MF, finding a frequency of SF3B1 (2%), 
U2AF1 (8%), and SRSF2 (17%)(Unpublished data). Table 
1 summarizes the frequency of all the genes discussed 
above. 
TABLE I. FREQUENCY OF MOLECULAR MUTATIONS AND CORRELATION WITH DISEASE PHENOTYPES IN 
MYELOFIBROSIS 
 
Gene Symbol Frequency (%) 
Associated Disease-Phenotype/ Impact on 
Survival Outcomes 
Studies 
JAK2                   40-59 
Higher Hgb 
Leukocytosis 
BM Fibrosis  
James et al, 2005 
Levine et al, 2005 
Baxter et al, 2005 




Beer et al, 2008 
Boyd et al, 2010 
Chaligne et al, 2008 
TET2  15-20 Anemia 
Vannucchi et al, 2013 
Brecqueville et al, 2012 
Delhommeau et al, 2009 
LNK <5 BM Fibrosis  
Ha et al, 2011 
St et al , 2010 
Pardanani et al, 2010 
DNMT3A 5-12 Poor Prognosis 
Vannucchi et al, 2013 
Stegelmann et al, 2011 
Abdel-Wahab et al, 2011 
IDH1/2 <5 Poor prognosis 
Vannucchi et al, 2013 
Brecqueville et al, 2012 
Tefferi et al, 2010 
ASXL1 17-25 BM Fibrosis/ Poor Prognosis 
Brecqueville et al, 2012 
Ricci et al, 2012 
Stein et al, 2011 
CBL <5 BM Fibrosis  
Schnittger et al, 2012 
Brecqueville et al, 2012 
Vainchenker et al, 2011 
EZH2 5-8 Poor prognosis 
Score et al, 2012 
Guglielmelli et al, 2011 
Ernst et al, 2010 
SF3B1 2-7 Ring sideroblast/ Good prognosis 
Visconte et al, 2012 
U2AF1 5-9 Poor prognosis 




Anemia/ Poor prognosis 
 
Lehmann et al, 2013 
Vannucchi et al, 2013 
Lasho et al, 2012  
ZRSR2                <5
§; 1.9† Unknown 
Thol et al, 2012 
Yoshida et al, 2011 
Table Legend: Summary of the frequencies, disease-phenotypes, and impact on survival outcomes of molecular mutations in Myelofibrosis. 
§the frequency refers to Myelodysplastic syndromes. †this frequency refers to a study conducted with whole exome sequencing 
Abbreviations. Hgb, hemoglobin; BM, bone marrow. 
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III. THE IMPACT OF MOLECULAR MUTATIONS  
ON THE PHENOTYPES OF MYELOFIBROSIS 
 
MF usually affects patients with advanced age (>65 
years old) and usually experience constitutional  
symptoms (90%), splenomegaly (90%), fatigue (70%), 
anemia (60%), circulating blasts (50%), thrombocytopenia 
(30%), pulmonary hypertension (30-40%) and higher risk 
of thrombosis (10%)[64-65].  
 
-Anemia and other hematologic abnormalities.  There 
are many proposed mechanisms on the cause of anemia in 
MF patients and includes  decrease bone marrow 
production due to decreased hematopoietic production 
sites in the BM due to fibrosis, splenic sequestration and 
consequent destruction of red cells in spleen, bleeding and 
autoimmune hemolysis. Yet, no distinctive molecular  
mutation has been proven to be the causative factor in the 
development of anemia in MF. Various studies that have 
looked at the clinical phenotypes of patients with MF with 
various molecular mutations have shown some some 
correlation between specific molecular subtypes and 
anemia. For example, patients with MPL and TET2 
mutations have lower Hgb levels [26,66]. Conversely, 
observations from our laboratory showed that JAK2 
mutant patients who also harbor spliceosome mutations 
have lower Hgb levels (8.98 vs 10.5 g/dL) and slightly 
higher leukocyte counts (27.5 vs 20.5 x10
9
/L) compared  
to JAK2 WT cases without spliceosome mutations 
(Unpublished data). Leukocytosis and thrombocytosis are  
other hematologic features of MF patients, the higher 
allele burden of JAK2V617F mutation has been associated 
with leukocytosis, reticulocytosis and splenomegaly while 
[67] MPL mutations has been associated with 
thrombocytosis [68].  
 
-Extramedullary hematopoiesis. Splenomegaly is the 
most common type of extramedullary hematopoiesis 
(EMH) in MF; however the definitive mechanisms 
involved in the development of splenomegaly remains  
elusive. The prevailing hypothesis for the development of 
splenomegaly includes cytokine stimulation of the spleen, 
deposition of BM erythroid precursors in the spleen and 
extramedullary hematopoietic compensation to sustain 
blood production. Little is known regarding the effects of 
molecular mutations in the causation of splenomegaly. 
Among various molecular mutations, patients with MF 
who carry JAK2 V617F and CBL mutations have enlarged 
spleens although the mechanisms whereby these 
mutations lead to EMH remain unclear [69]. 
 
-Bone Marrow Fibrosis. In MF, BM fibrosis is one of the 
important disease features and represents one of the major 
criteria for diagnosis. Fibrotic deposition can be detected 
using reticulin and/ or trichrome stains. It was alluded that 
fibrosis is the result of a reactive process of normal 
fibroblasts stimulated by aberrant cytokine activation 
resulting in the deposition of BM stromal fibers.  
Cytokines like transforming growth factor beta (TGF-β), 
platelet derived growth factor (PDGF,) and fibroblast 
growth factor (FGF) have been linked to the formation of  
fibrosis in BM [70-71]. Disruption of MPL function can 
cause over-activation of the thrombopoietin-receptor, that 
can over-stimulate megakaryocytes to release several 




IV. THE IMPACT OF MOLECULAR MUTATIONS  
ON PROGNOSIS OF MYELOFIBROSIS 
 
A number of molecular mutations and genetic 
modifiers like single nucleotide polymorphisms have been 
described in MPN with some associated with poor 
prognosis and leukemia transformation [72]. For instance, 
it has been shown that the presence of the A3669G 
polymorphism in an MF patient with JAK2V617F 
mutation is associated with shorter overall survival and 
blast transformation free survival [73]. It has also been 
suggested that low JAK2V617F allele burden is associated 
with pancytopenia and higher susceptibility to infections 
which can result in lower overall survival [74].  
Additionally, presence of mutations in molecular 
markers like IDH1/2, ASXL1, SRSF2 or EZH can 
independently predict shorter overall survival [75]. Some 
of these mutations (eg, IDH1/2 and SRSF2) have also 
been associated with inferior leukemia-free survival [75].  
Despite the high frequency of JAK2V617F and TET2 
mutations in MF, both genetic changes do not appear to 
affect survival outcomes [34,69]. Conversely, MPL 
mutations are not associated with inferior outcomes. The 
existence of EZH2 mutations in MDS was associated with 
poor overall survival and complex cytogenetic 
abnormalities. However, the same finding has not been 
established in MF [76].  
In our studies, the presence of SRSF2 mutations 
contributed to a significant increase in the percentage of 
BM blasts and a higher incidence of progression to AML 




V. THE IMPACT OF MOLECULAR MARKERS  
ON RESPONSE TO TREATMENTS IN 
MYELOFIBROSIS 
 
 The presence of molecular mutations can alter the 
response to therapies in MDS, MDS/MPN, and secondary 
AML [77]. It was suggested that the presence of TET2 
mutations could have negative impact on response to JAK 
inhibitors [78].  
 However, in other myeloid malignancies like MDS 
and AML, patients carrying TET2 and DNMT3A 
mutations responded better to therapies specifically 
hypomethylating (HMA) agents [79].  
 In MF, the presence of JAK2V617F mutation has 
been shown to be a predictor of better response to 
lenalidomide [80].  
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VI. CONCLUSIONS 
 
In the JAK-inhibitor era, the management of some 
disease related features of MF has improved although 
there are still a lot of unmet needs including management 
of allele burden, treatment of cytopenias, and prevention 
of clonal evolution and therapy of patients who have 
evolved to AML. The discovery of molecular mutations 
has been expedited by next generation genomic 
technologies and this may lead to the identification of 
better therapeutic options for this disease similar to 
advancements being made in other hematologic 
malignancies [79,81]v (unpublished data). It may also 
allow us to identify patients who may respond to 
treatments and those that are likely to develop resistance 
or relapse from their therapies. The discovery of novel 
genetic signatures and alternative signaling pathways will 
hold the key to understanding the basic help 
pathophysiology of MF and will open new avenues in the 
management of MF and other MPNs that can improve 
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